Project NEUROSENSE (NEUROendocrine SENSor for Sudden Unexpected Death in Epilepsy prediction and prevention) has been approved in the highly-competitive context of EU Horizon EUROPE Pathfinder Open call, with 4M€ funding. The project will be developed under the leadership of i3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto with Portuguese Biotech start-up BIOSTRIKE, joining a consortium that involves Karolinska Institutet (Sweden), Centre National de la Recherche Scientifique (France), Centre Hospitalier Universitaire Vaudois (Switzerland), Filadelfia (Denmark) and Kinetikos – Driven Solutions S.A. (Portugal).
Sudden Death in Epilepsy (SUDEP) is the leading cause of epilepsy-related death with no predictive medical device or preventive treatment available. NEUROSENSE ultimate goal is to create and develop the first companion medical device prototype supported by artificial intelligence (AI) to anticipate life-threatening seizures and trigger an automatic drug administration to prevent SUDEP. Used as an efficacy endpoint in non-clinical and clinical studies, the envisioned medical device will also enable pharmaceutical companies to develop the first generation of drugs targeting SUDEP prevention, fulfilling its contribution to the eradication of the leading cause of epilepsy-related death.
NEUROSENSE framework is uniquely positioned to succeed and raise the Europe competitiveness in the Epilepsy area, specifically in the strategic epilepsy AI-driven medical device domain enabling for the first time a continuous and unlimited SUDEP risk assessment through the use of synthetic and semi-synthetic biorecognition elements as Key Enabling Technology for the for continuous and fully-automated SUDEP risk assessment.
The kick-off of NEUROSENSE is scheduled for June 2022.
Contact: info@biostrike.pt
